NCT02446743 - Combined Study - Phase 3b MenB Long Term Persistence in Adolescents | Biotech Hunter

Enrollment

531

Participants

Timeline

Start Date

November 17, 2015

Primary Completion Date

September 23, 2016

Study Completion Date

September 23, 2016

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)

One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.

Trial Locations (12)

GSK Investigational Site, Carlton

GSK Investigational Site, Sherwood

GSK Investigational Site, North Adelaide

GSK Investigational Site, Subiaco

GSK Investigational Site, Santiago

GSK Investigational Site, Santiago

GSK Investigational Site, Truro

GSK Investigational Site, Greater Sudbury

GSK Investigational Site, Newmarket

GSK Investigational Site, Toronto

GSK Investigational Site, Toronto

GSK Investigational Site, Woodstock